that the incidence of AEG is strikingly different from that in Western countries. This article reviews the clinicopathological features of AEG in terms of the differences between Western and Eastern countries. In addition, this report also evaluates the treatment strategies for AEG based on the results of major clinical trials.
Siewert classifi cation (Fig. 1)
An appropriate and commonly used classifi cation is essential for the analysis of the characteristics of a disease and the establishment of the optimal treatment strategy. Siewert and Stein [6] proposed a new classifi cation of AEG in 1996, which was based on topographic anatomical criteria. AEG was divided into three types, each of which had different characteristics, thereby infl uencing the selection of the surgical strategy. Type I is defi ned as tumors in which the center is located 1 to 5 cm above the esophagogastric junction (EGJ), regardless of invasion to the EGJ; type II is defi ned as tumors invading the EGJ, in which the center is located between 1 cm above and 2 cm below the EGJ; and type III is defi ned as tumors invading the EGJ, in which the center is located 2 to 5 cm below the EGJ (Fig. 1 ). This classifi cation was approved at the consensus conference of the International Gastric Cancer Association (IGCA) and the International Society for Diseases of the Esophagus (ISDE) [7] , and has been accepted and is now used worldwide. The Siewert subtype should be determined prospectively, based on the fi ndings of endoscopy, contrast radiography, and computed tomography. A defi nition of anatomical cardia is determined by the fi ndings of endoscopy [8] .
Introduction
The incidence of adenocarcinoma of the esophagus and esophagogastric junction (AEG) is dramatically increasing in Western countries [1] [2] [3] . Moreover, in many Western countries, the incidence of AEG is increasing more rapidly than that of any other type of neoplasm [4] . Siewert proposed a classifi cation of AEG, based on the anatomical location, in 1996, and it has been accepted worldwide. This classifi cation divides AEG into three subtypes (Fig. 1) . A retrospective analysis showed that more than 80% of AEGs in Western countries were in an advanced stage, and the prognosis was quite poor, with a 5-year survival rate of less than 30% [5] . Therefore, it is necessary to establish an optimal treatment strategy for AEG in Western countries. On the other hand, several reports from Eastern countries indicate metaplasia (so-called Barrett's esophagus); the latter is considered to be deeply associated with the development of AEG [9, 10] . The prevalence of Barrett's esophagus in patients with type I tumors is higher than that in patients with type II/III tumors, in both Western and Eastern countries [11, 12] .
Type II tumors are true AEG arising from the junctional epithelium; however, some type II tumors can arise from the same origin as type I tumors, and some can arise from the same origin as type III tumors. Many previous studies have demonstrated that the characteristics of type II tumors are more like those of type III tumors than those of type I tumors, thus indicating that the origin of type II tumors is similar to that of type III tumors [5, 7, 10] .
Type III tumors arise from the gastric mucosa, and this origin might be associated with Helicobacter pylori and atrophic gastritis [10, 13] . Tumors whose center is located 2 to 5 cm below the EGJ are classifi ed as non-AEG or true gastric cancers when the tumors do not invade the EGJ. The tumor classifi cation changes to AEG type III when they invade the EGJ by horizontal progression. Therefore, subcardial gastric cancers are classifi ed as type III tumors when they are enlarged. Type III tumors should be treated as gastric cancers invading the EGJ, considering the origin of the tumors.
In summary, AEG may contain two distinct etiologies [13] . It is often diffi cult to determine the tumor origin, especially in advanced cases. The examination of biomarkers may thus provide the key to accurately determine the tumor origin [14, 15] .
Incidence and characteristics

Incidence of AEG in Western countries
Carrie described, in his review, that the fi rst case of adenocarcinoma of the esophagus was reported by White in 1898 [16] . In several case series in the 1950s, the incidence of adenocarcinoma of the esophagus was reported to be 8% in the United Kingdom [17] and 10% in the United States [18] . These types of tumors were believed to arise from ectopic patches of gastric mucosa in the esophagus. Barrett [19] fi rst described the columnar epithelium lining the lower part of the esophagus at that time.
Once a rare tumor [20] , the incidence of AEG is currently increasing faster than that of any other type of tumor; especially, the incidence of AEG types I and II is increasing in the United States [2] . The rate of increase has outpaced that of the next most commonly increasing tumor, melanoma, by approximately three times [2, 21, 22] . Similar trends are also reported in the United Kingdom, Scotland, Norway, Sweden, Denmark, France, Switzerland, Australia, and New Zealand [3, [23] [24] [25] [26] [27] [28] [29] [30] . This increase began in the 1970s, and it seems to be most prominent in white men [1, 2] .
Incidence of AEG in Eastern countries
In contrast to reports in Western countries, there are only a few reports of the incidence of AEG in Eastern countries. Shibata et al. [31] reported on trends in the incidence of adenocarcinoma of the esophagus in Japan, and indicated that no increase in the incidence of these tumors was observed. The proportion of AEG among upper gastrointestinal (GI) tract cancers at Kanagawa Cancer Center was analyzed and the incidence had not changed in 20 years (Table 1) . Chung et al. reported similar results in Korea [32] . Conversely, Kusano et al. [33] reported a slight increasing trend of AEG in Japan in a retrospective analysis of lesions resected as gastric cancer, although they did not include cases which were treated as esophageal cancer. There is no obvious evidence that indicates a rapid increase of AEG in Eastern countries. (Table 2) The frequency of the three types of AEG is strikingly different between Western and Eastern countries. Type I tumors occur less frequently in Eastern countries than [11] , fi ndings that were similar to the results in China [12] . Type III disease seems to be more progressive than types I and II, and this trend is similar in Western and Eastern countries. This fi nding of type III disease being more progressive than types I and II is not surprising, because type III represents the progression of a subcardial gastric cancer which originates from the gastric mucosa 2 to 5 cm below the EGJ, and the size of the tumor tends to be larger than that of type II [36] . The clinicopathological features of AEG are quite similar in Western and Eastern countries, except for the prevalence of type I tumors, most of which arise from Barrett's esophagus. The established risk factors for adenocarcinoma of the esophagus are Barrett's esophagus, gastroesophageal refl ux, and obesity; conversely, Helicobacter pylori infection might reduce the risk [38] . The difference in the prevalence of type I tumors in Western and the Eastern countries may be explained by differences in the proportions of obese patients and differences in the prevalence of H. pylori infection.
Clinicopathological characteristics: similarities and differences between Western and Eastern countries
The incidence of gastric cancer in the United States (noncardial cancer) has decreased gradually since the 1930s, whereas that of AEG has increased rapidly since the 1970s. The decrease in the incidence of gastric cancer is associated with the decrease in the H. pylori infection rate; thus, the increase of AEG might have followed the decrease of gastric cancer, after several decades. Therefore, there may be a dramatic increase of AEG in the near future in Eastern countries where there is currently a decrease in the rate of gastric cancer, although there is no evidence that indicates an increase of AEG, as described previously.
Treatment strategies for resectable disease
Surgical strategy
A multivariate analysis demonstrated an R0 resection to be an independent predictive factor associated with survival, as well as T, N, and M factors (Table 3) . Siewert et al. also reported that an R0 resection was a strong prognostic factor in patients with AEG [39] . Therefore, the primary goal of a surgical resection of AEG is the complete removal of the primary tumor and lymph nodes. The reported occurrence of mediastinal lymph node metastasis of AEG is 7.1%-40.8% [40] [41] [42] [43] [44] . The necessity of a prophylactic mediastinal nodal dissection remains controversial [42] [43] [44] . Two major trials were conducted, in the Netherlands and in Japan, to clarify the optimal surgical approach and suffi cient extent of mediastinal lymph node dissection.
Phase III trial in the Netherlands (Dutch trial) [45] . The fi rst of the major trials mentioned above was a phase III trial performed in the Netherlands in 1994-2000. This study was designed to elucidate the optimal surgical approach and the extent of lymph node dissection for patients with lower esophageal adenocarcinoma (type I) and adenocarcinoma of the gastric cardia (type II). The study evaluated the superiority of a transthoracic esophagectomy with an extended en-bloc lymphadenectomy via the right thoracic approach (RTA) to a transhiatal esophagectomy (TH). The study was performed at two high-volume centers in Amsterdam and Rotterdam. In the TH group, the esophagectomy was performed under direct vision through the enlarged hiatus of the diaphragm to the inferior pulmonary vein, and the esophagus was bluntly resected. A gastric tube was constructed, and an esophagogastrostomy was performed in the neck. The lymph nodes adjacent to the tumor were dissected en bloc, and the left gastric artery was resected for the removal of the lymph nodes. No cervical or upper-middle mediastinal lymphadenectomy was performed. The celiac lymph nodes were not dissected unless there was clinical evidence of metastasis.
In the patients in the RTA group, a mediastinal lymphadenectomy was performed, as well as an abdominal lymphadenectomy including the paracardial, lesser-curvature, left gastric artery, celiac trunk, common hepatic artery, and splenic artery nodes. The hypothesis was that an RTA would yield a 15% better 2-year survival rate than TH, with an alpha error of 0.05 and beta error of 0.1. The required sample size was calculated to be 220.
The main results were published in 2002 [45] . The 5-year overall survival rate was better in the RTA group than in the TH group (39% vs 29%), although the difference did not reach statistical signifi cance. On the other hand, pulmonary complications and chylous leakage were observed more frequently in the RTA group in comparison to the TH group (57% vs 27%; P < 0.001 and 10% vs 2%; P = 0.002). The durations of intensive care unit (ICU) stay and hospital stay were longer in the RTA group than in the TH group (6 vs 2 days; P < 0.001 and 19 vs 15 days; P < 0.001). In-hospital mortality did not differ between the groups (4% vs 2%; P = 0.45). An additional analysis of the updated survival data was published in 2007 [46] . The 5-year survival rates did not differ between the groups (36% in the RTA group and 34% in the TH group; P = 0.71); however, a survival benefi t of 14% was seen in the RTA group in the patients with a type-I tumor (51% vs 37%; P = 0.33). The P value did not reach statistical signifi cance, and this may have been due to a type-II error. On the other hand, the 5-year locoregional disease-free survival was significantly better in the RTA group, when stratifi ed to the patients having a type I tumor and one to eight positive nodal metastases (64% vs 23%; P = 0.02).
In conclusion, an extended transthoracic resection was found to be more hazardous surgery in regard to morbidity than a transhiatal esophagectomy, although mortality did not differ between these two groups. Extended surgery could therefore be recommended only for patients with type I tumors; however, it could not be recommended for patients with type II tumors.
Phase III trial in Japan (JCOG 9502) [47] . The above Japan Clinical Oncology Group (JCOG) phase III trial was conducted to clarify the signifi cance of the left thoracoabdominal approach (LTA) for patients with type II/III AEG, in comparison to the transhiatal approach (TH). Patients were eligible if they had AEG through the submucosa, which invaded less than 3 cm into the esophagus. The patients in the TH group received a total gastrectomy with D2 lymphadenectomy (including splenectomy) plus paraaortic nodal dissection (lateral to the aorta and above the left renal vein). The patients in the LTA group received a thorough mediastinal nodal dissection below the left inferior pulmonary vein, as well as the same procedure in the abdominal cavity. The fi rst interim analysis was done when the 165 patients were enrolled. The 5-year survival rate was estimated to be 53.4% (95% confi dence interval [CI],38.1-68.6) in the TH group, and 38.9% (95% CI, 22.4-55.4) in the LTA group (P = 0.93). The probability of LTA being significantly better than TH at the fi nal analysis was considered to be quite low (3.65%); consequently, the accrual 34% ; P = 0.06). In-hospital mortality was also higher in the LTA group (4% vs 0%; P = 0.25). This result suggested that an LTA for type II/III tumors did not provide a survival benefi t; on the contrary, it might increase the surgical morbidity and mortality. In conclusion, LTA is therefore not recommended for type II/III tumors.
Optimal surgical strategy for AEG
The results of these two trials are summarized in Table  4 . These two phase III studies and the retrospective analyses examining the pattern of the lymph node metastases suggest the optimal surgical approaches and the extent of the nodal dissection for a resectable AEG. The results of the Dutch trial [45] indicated that RTA with a mediastinal lymph node dissection may be recommended for type I tumors, if the patients can tolerate the surgery. Patients with type I tumors in the RTA group underwent a D2 abdominal lymphadenectomy. It is unclear whether or not the D2 abdominal dissection affected the results. A thoracoabdominal approach with a radical mediastinal nodal dissection could not improve the survival for patients with type II tumors in both phase III trials; however, it did increase the surgical risk. Therefore, the transhiatal approach is recommended for type II tumors.
The JCOG 9502 trial showed that there were no differences in the survival rates or hazard ratios between type II and type III tumors. The principle of the surgical strategy did not differ. A transhiatal extended gastrectomy is the preferable approach for type II and type III tumors. A D2 plus partial paraaortic nodal dissection (PAND) was performed in both groups in the JCOG 9502 trial, while D1 was performed in the control arm and D2 in the test arm of the Dutch trial. Which abdominal dissection should therefore be recommended for types II and III? Strictly speaking, there is no evidence to indicate the appropriate abdominal nodal dissection for AEG types II and III. However, many previous reports have indicated that abdominal nodal metastases are frequently observed in type II/III tumors [11, 36] . One analysis showed that 32.9% of type II tumors had involvement of the lymph nodes along the major branched arteries (the left gastric artery, common hepatic artery, splenic artery, and celiac axis), and the rate was 50% in type III tumors [36] . Siewert and Stein also reported similar results; 25% nodal involvement in type II tumors and 39% in type III tumors [11] . These reports clearly indicate that abdominal nodal metastases are frequently observed in AEG type II/III tumors, as in true gastric cancer. Moreover, the major recurrence patterns are nodal, peritoneal, and liver metastases after curative surgery in AEG types II and III, from the results of the JCOG 9502 trial, with these patterns being the same as those of true gastric cancer [47] . Therefore, the extent of a nodal dissection for AEG type II/III should be same as that applied for gastric cancer. A Japanese phase III trial comparing D2 and D2+PAND (JCOG 9501) demonstrated that D2+PAND could not improve the survival of patients with gastric cancer [48] . Therefore, D2 became the standard surgery for gastric cancer in Japan. On the other hand, a Taiwanese phase III trial comparing D1 and D3 (which is a D2 dissection according to the present defi nition) clearly showed that D2 could improve survival [49] . Although two phase III trials performed in Europe comparing D1 and D2 did not confi rm the survival superiority of D2 [50, 51] , there was a lot of criticism of the quality of the D2 surgery; it seemed that this surgery led to the results showing an extremely high mortality. Therefore, an abdominal D2 lymphadenectomy is recommended for patients with type II/III tumors, unless D2 increases the surgical risk. In summary, AEG type I should be treated as esophageal cancer, while types II and III should be treated as true gastric cancer.
Multimodal treatment
Although surgery is the primary modality that can cure AEG cancer, the long-term outcome is not satisfactory, even after an R0 resection. The results of surgical resection, not including perioperative chemotherapy, were obtained from the two randomized controlled trials. The 5-year survival rate in the Dutch trial [46] [47] , which may suggest the limitations of surgery. Therefore, perioperative chemotherapy may be required to improve the prognosis of AEG.
Perioperative chemotherapy (Table 5) A phase III trial of adjuvant chemotherapy for gastric cancer was performed in Japan (ACTS-GC) to clarify the effect of S-1 in stage II/III patients who underwent a curative D2 surgery, and its survival benefi t [52] . The 3-year overall survival rate was 80.1% in the S-1 group and 70.1% in the surgery-only group, and this difference was signifi cant (P = 0.003). The result of this phase III trial has affected the strategy for the treatment of gastric cancer in Japan, and the Japanese guidelines for gastric cancer have been revised. The relevance of this result for patients with AEG is unknown, because the ratio of AEG among the patients enrolled was not shown in this trial. However, the results of the ACTS-GC trial could be applicable to AEG type II and type III tumors, as these tumors have characteristics similar to those of true gastric cancer in terms of lymph node metastasis and recurrence patterns [47] . Postoperative S-1 chemotherapy could be a standard for AEG type II and type III tumors in the countries in which abdominal D2 surgery is the standard, although ethnic differences must be considered in the effects of S-1. Neoadjuvant chemotherapy for esophageal cancer is associated with an improvement in the prognosis [53] . The Medical Research Council (MRC) Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial compared perioperative cisplatin-based chemotherapy plus surgery to surgery alone, and found a signifi cant survival improvement of 13% at 5 years with multimodal treatment (36% vs 23%) [54] . The initial design of this trial included patients with gastric carcinomas, and the eligibility criteria were extended to include adenocarcinomas of the lower third of the esophagus, on the basis of the increased incidence of AEG. Seventy-three of the 503 patients enrolled (14.5%) had tumors of the lower esophagus, and 58 (11.5%) patients had tumors of the esophagogastric junction. Although the number of patients was relatively small, no difference in the treatment effect was observed according to the site of the primary tumor (P for interaction = 0.25). Recently, the effi cacy of perioperative chemotherapy was confi rmed by a French Intergroup trial, in which approximately 75% of the patients enrolled had tumors located in the esophagogastric junction [55] . These trials suggested that perioperative chemotherapy, when combined with limited nodal dissection, improved the prognosis of patients with AEG tumors. However, the extent of abdominal nodal dissection was usually less than D2 in these trials, which is quite different from the Japanese standard D2 dissection. A difference in the extent of local control infl uences the overall effect of the treatment. Therefore, the results shown in these trials would not be applicable to countries in which the standard surgery is D2.
Perioperative chemoradiotherapy (Table 6) The role of radiotherapy, specifi cally concurrent chemoradiotherapy, remains controversial. Macdonald et al. reported the signifi cance of chemoradiotherapy after curative surgery in 2001 [56] . The median duration of survival was 36 months in the chemoradiotherapy group and 27 months in the surgery-only group, with a median follow-up period of 5 years, and the difference was signifi cant (P = 0.005). This study was a valuable trial, for this is the fi rst report which demonstrated the effect of adjuvant therapy in gastric cancer. However, the most common location of the primary tumor was the distal portion of the stomach (53% in the chemoradiotherapy group, 56% in the surgery-only group), and the ratio of cardia tumors was relatively small (21% in the chemoradiotherapy group, 18% in the surgery-only group).
The association between AEG and true gastric cancer was not shown in this trial. Moreover, the extent of abdominal nodal dissection was mostly D0 or D1, which was quite different from Japanese D2 surgery. A meta-analysis showed that preoperative chemoradiotherapy improved survival in resectable esophageal cancer in comparison to surgery alone, although the extent of nodal dissection was limited and the surgeryrelated mortality was signifi cantly higher in preoperative chemoradiotherapy followed by surgery than surgery alone [57, 58] . There is little data comparing preoperative chemoradiotherapy to chemotherapy. Recently, a randomized controlled trial was reported from Germany, which compared preoperative chemoradiotherapy with preoperative chemotherapy in patients with locally advanced AEG [59] . An abdominal D2 dissection was performed in type II and type III tumors, whereas a transthoracic esophagectomy or transhiatal esophagectomy was used in type I tumors. The patients who received preoperative chemoradiotherapy showed a higher 3-year survival rate in comparison to the patients who received preoperative chemotherapy (47.4% vs 27.7%), although the difference did not reach statistical signifi cance (P = 0.07). In summary, perioperative chemoradiotherapy contributes to survival when combined with a limited nodal dissection. It is still unclear whether chemoradiotherapy could improve the prognosis when combined with an extended nodal dissection. (Table 7) Patients with systemic metastatic disease are recommended to receive systemic chemotherapy. The regimen of fl uorouracil plus cisplatin (FP) is considered to be the standard, based on earlier trials in patients with squamous cell carcinoma [60, 61] . Phase III trials performed in Japan show that the response to FP therapy does not differ between the histological types, with a response rateof 33.3% in squamous cell carcinoma (JCOG 9407 Hazard ratio in the oxaliplatin group, as compared with the cisplatin group [62) and a response rate of 34% in adenocarcinoma (JCOG 9205). An FP-based regimen is regarded as the standard therapy for gastric cancer in both Western and Eastern countries. Randomized trials in Western countries have demonstrated higher response rates and survival benefi ts with a regimen of epirubicin, cisplatin, and infused fl uorouracil (ECF) [63, 64] , and the effi cacy of this regimen has also been confi rmed by a meta-analysis [65] . Of these trials, one trial demonstrated a higher response rate in the patients with AEG than in those with gastric cancer (48.0% in AEG vs 37.0% in gastric cancer; P = 0.041) [64] . The REAL-2 trial demonstrated that cisplatin and fl uorouracil in the ECF regimen could be replaced by oxaliplatin and capecitabine, respectively [68] . On the other hand, Van Cutsem et al. [66] demonstrated a survival benefi t of a regimen of docetaxel, cisplatin, and fl uorouracil (DCF) in 2006. In this trial, 22.1% (98/444) of the patients had primary tumors located in the esophagogastric junction, although the report did not show differences in treatment effects between the primary tumor sites. A phase III trial performed in Japan with a regimen of S-1 plus cisplatin demonstrated a signifi cant survival benefi t in comparison to S-1 alone [67] , although the proportion of patients with AEG was not shown. In the light of these fi ndings, such fl uoropyrimidine and platinum-based regimens may be recommended for AEG patients with metastatic disease. The ToGA trial was performed for patients with human epithelial growth factor receptor (HER)-2-positive gastric carcinoma and AEG as a global trial and demonstrated that 5-fl uorouracil (5-FU) or capecitabine/ cisplatin with trastuzumab could improve the prognosis, in comparison to the regimens without trastuzumab [69] . This trial included 16.6%-19.7% of patients with AEG and there was no interaction between gastric cancer and AEG. Therefore, fl uoropyrimidine/cisplatin with trastuzumab could be a standard chemotherapy for HER-2-positive AEG tumors.
Treatment strategies for advanced disease
Conclusions
The incidence of AEG is increasing dramatically in Western countries but not in Eastern countries. The incidence of Siewert type I tumors is less frequent in Eastern countries than in Western countries. On the other hand, other clinicopathological features, including patient's age, the male-to-female ratio, the pathological grade, tumor progression, and prognosis are similar in Western and Eastern countries. Surgically, AEG type I should be treated as esophageal cancer, while types II and III should be regarded as true gastric cancers. No phase III trials have yet identifi ed a signifi cant interaction comparing hazard ratios for death between AEG and true gastric cancers in the subset analyses.
